ISPOR - EE568 Does the Introduction of an Infliximab Biosimilar Always Result in Savings for Hospitals? A Descriptive Study Using Real-World Data

Full Text

EE568 Does the Introduction of an Infliximab Biosimilar Always Result in Savings for Hospitals? A Descriptive Study Using Real-World Data

Abstract

Authors

M. Krstic J.C. Devaud F. Sadeghipour J. Marti

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now